Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (ACTRN12625001083482) titled 'Sapu003 in Combination with Exemestane in Post-Menopausal Women with HR+, HER2-Negative Advanced or Metastatic Breast Cancer' on Oct. 3.
Study Type: Interventional
Study Design:
Purpose: Treatment
Allocation: Non-randomised trial
Primary Sponsor: Ingenu CRO Pty. Ltd
Condition:
Breast Cancer
Breast Cancer
Cancer - Breast
Intervention:
The investigational intervention consists of Sapu003 (Everolimus) for Injection, administered intravenously over 30 minutes once weekly in 4-week (28-day) cycles. Dose escalation will follow the Bayesian Optimal Interval (BOIN) design to determine the Maximum Tolerated Dose...